The current validation study on tumor samples from the TEAM trial aimed to assess the ability of CAB to predict the risk of distant recurrence at ten years for the first time, for postmenopausal patients with early breast cancer, HR-positive, HER2-negative, node-negative or positive disease. The gene discussed is ERBB2; the disease is breast carcinoma.